biostudies-literatureClavreul ACancéropôle Grand OuestFrench National Cancer InstituteGIS IBiSALigue Nationale Contre le Cancer5510https://www.ebi.ac.uk/biostudies/studies/S-EPMC9688811biostudies-literatureUnknown14(22)Safe maximal resection followed by radiotherapy plus concomitant and adjuvant temozolomide (TMZ) is universally accepted as the first-line treatment for glioblastoma (GB), but no standard of care has yet been defined for managing recurrent GB (rGB). We used the French GB biobank (FGB) to evaluate the second-line options currently used, with a view to defining the optimal approach and future directions in GB research. We retrospectively analyzed data for 338 patients with de novo isocitrate dehydrogenase (IDH)-wildtype GB recurring after TMZ chemoradiotherapy. Cox proportional hazards models and Kaplan-Meier analyses were used to investigate survival outcomes. Median overall survival after first surgery (OS1) was 19.8 months (95% CI: 18.5-22.0) and median OS after first progression (OS2) waCancersManagement of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?PMC9688811NAINCA_6298Caire FLe Reste PJQuillien VDehais CSanson MLoiseau HMokhtari KDi Stefano ALBergemer-Fouquet AMGele PGraillon TMarguet FFaisant MAlmairac FLantuejoul SYordanova YHorodyckid CGaillard SEmery EDesenclos CConstans JMRigau VRousseau AZemmoura IDufay NLemee JMBonnin AFrenel JSLoussouarn DAutier LRousseau NBurel-Vandenbos FMeyronet DGay ERech FLabrousse FFeuillard JCornu PBourg VGauchotte GBlanchet OBouillot-Eimer SRicard DCollaborators of the FGB networkAubriot-Lorton MHPallud JGuilain NLippert EFermeaux VHerpe YEVoirin JReyns NNetwork FBoone MGhaleh BDucray FDufour HHoang-Xuan KSeizeur RChinot OMenei PGuyotat JLanglois OFigarella-Branger DMetellus PMossuz PChiforeanu DCMarniche ALerintiu FNiel PSoulard GMaurage CADelattre JYKerdraon OTurlin BHerault OBlonski MAugereau PHeller RGoze CMosnier JFTebbakha RVarlet PQuintin-Roue IAhle GQuillard-Muraine MDubus PVilla CFarah WClavreul ABauchet LfalseManagement of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?Safe maximal resection followed by radiotherapy plus concomitant and adjuvant temozolomide (TMZ) is universally accepted as the first-line treatment for glioblastoma (GB), but no standard of care has yet been defined for managing recurrent GB (rGB). We used the French GB biobank (FGB) to evaluate the second-line options currently used, with a view to defining the optimal approach and future directions in GB research. We retrospectively analyzed data for 338 patients with de novo isocitrate dehydrogenase (IDH)-wildtype GB recurring after TMZ chemoradiotherapy. Cox proportional hazards models and Kaplan-Meier analyses were used to investigate survival outcomes. Median overall survival after first surgery (OS1) was 19.8 months (95% CI: 18.5-22.0) and median OS after first progression (OS2) wa2022-01-01T00:00:00Z2022 Nov2025-04-26T05:17:18.194Z2025-04-06T11:29:10.272ZS-EPMC96888113642860410.3390/cancers14225510